Clinical Trial Update: TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dose escalation tolerability of abemaciclib in HR-positive, HER2-negative early-stage breast cancer; the study is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• High-risk Breast Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer, Early-stage Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING